Federal Government Subsidizes First Endometriosis Drug in 30 Years

The listing of Visanne on the PBS will significantly reduce costs for Australians living with the debilitating condition.

Visanne, a daily tablet for managing endometriosis symptoms, will be added to the Pharmaceutical Benefits Scheme (PBS), cutting annual treatment costs from over $800 to $380, or $90 for concession card holders.
The drug, also known as dienogest, works by suppressing ovulation and menstruation, helping to shrink and control abnormal tissue growth associated with endometriosis.
Endometriosis affects nearly 1 million Australians, with symptoms including chronic pain, heavy menstrual bleeding, fatigue, and fertility issues, often taking over six years to diagnose.
The federal government has invested over $107 million in endometriosis research, treatment, and intervention, with this subsidy marking a major step forward in accessible care.
Advocates and medical experts have praised the decision, emphasizing the importance of affordable treatment options for improving quality of life and reducing hospital admissions caused by the condition.